Intrommune Therapeutics

Executive Summary

Intrommune Therapeutics is a private biotechnology company headquartered in New York City, founded in 2015, dedicated to developing a novel oral mucosal immunotherapy (OMIT) platform for the treatment of food allergies. The company's lead product candidate is a toothpaste formulation that delivers allergenic proteins to the oral mucosa, aiming to induce immune tolerance in a safe, convenient, and disease-modifying manner. This approach addresses the significant unmet need in food allergy management, where current standard of care relies on strict allergen avoidance and emergency epinephrine use. Intrommune's OMIT platform has the potential to improve patient compliance and quality of life through daily at-home administration. The company's initial focus is on peanut allergy, with additional candidates for other food allergies in preclinical development. Early clinical data from Phase 1/2 trials have shown promising safety and immunological signals, supporting advancement toward later-stage studies. Intrommune's technology leverages a well-established concept of oral tolerance but innovates via a simple, patient-friendly delivery system. The company is privately held and has not disclosed detailed financials or valuation. Its progress will depend on successful clinical outcomes, regulatory interactions, and potential partnerships to fund pivotal trials. Given the large global patient population and the limitations of existing treatments, Intrommune's OMIT platform could represent a paradigm shift in food allergy therapy. However, as a private company with limited public data, the risk profile remains elevated, and key milestones over the next 12-18 months will be critical to validating the platform's potential.

Upcoming Catalysts (preview)

• H2 2026Initiation of Phase 2b/3 pivotal trial for peanut allergy OMIT toothpaste60% success
• Q3 2026Presentation of updated Phase 2 safety and efficacy data at a major allergy conference (e.g., AAAAI/EAACI)70% success
• Q4 2026Announcement of strategic partnership or licensing deal for OMIT platform50% success